Please assess the completion status of the following clinical trial:

Trial Title: Candesartan Effect in Second Stage Arterial Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Stage II essential hypertension (SBP≥ 160 or DBP≥100 mmHg), untreated, or treated with a maximum of 2 class of antihypertensive drugs~Exclusion Criteria:~* Current serum-creatinine \>3 mg/dL, Current serum-potassium \>5.5 mmol/L, 16.~* Pregnant or lactating women or women of childbearing potential who were not protected from pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Candesartan cilexetil 16mg monotherapy
- 2 (Type: EXPERIMENTAL): Candesartan cilexetil 16mg/HCT combination therapy
- 3 (Type: ACTIVE_COMPARATOR): candesartan cilexetil 32mg monotherapy
- 4 (Type: EXPERIMENTAL): Candesartan Cilexetil 32 mg/HCT combination therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).